At a glance
ClinicalIndex Comparison RecordN/ACompleted· 11 enrolled
Drug / intervention
perflutren lipid microspheres +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Feasibility of 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
In Brief
A clinical study evaluating perflutren lipid microspheres and 3D ultrasound for Liver Cancer and 3 related conditions. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer, Liver Tumor, Hepatocellular Carcinoma, Liver Carcinoma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
First PostedApr 2015
Primary CompletionJun 2022
TodayJul 2026
First PostedApr 23, 2015
Enrollment StartNov 18, 2014
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 11.2 years ago
Interventions
perflutren lipid microspheresdrug
3D ultrasoundother